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ABSTRACT
CTG•CAG repeat expansions cause at least twelve
inherited neurological diseases. Expansions require
the presence, not the absence, of the mismatch
repair protein MutS (Msh2-Msh3 heterodimer). To
evaluate properties of MutS that drive expansions,
previous studies have tested under-expression, AT-
Pase function or polymorphic variants of Msh2 and
Msh3, but in disparate experimental systems. Addi-
tionally, some variants destabilize MutS, potentially
masking the effects of biochemical alterations of the
variations. Here, human Msh3 was mutated to selec-
tively inactivate MutS. Msh3−/− cells are severely
defective for CTG•CAG repeat expansions but show
full activity on contractions. Msh3−/− cells provide a
single, isogenic system to add back Msh3 and test
key biochemical features of MutS on expansions.
Msh3 overexpression led to high expansion activity
and elevated levels of MutS complex, indicating that
MutS abundance drives expansions. An ATPase-
defective Msh3 expressed at normal levels was as
defective in expansions as Msh3−/− cells, indicating
that Msh3 ATPase function is critical for expansions.
Expression of two Msh3 polymorphic variants at nor-
mal levels showed no detectable change in expan-
sions, suggesting these polymorphisms primarily af-
fect Msh3 protein stability, not activity. In summary,
CTG•CAG expansions are limited by the abundance
of MutS and rely heavily on Msh3 ATPase function.
INTRODUCTION
CTG•CAG repeat expansions are the underlying genetic
cause for at least 12 inherited neurological disorders, includ-
ing Huntington’s disease (HD), myotonic dystrophy type 1
(DM1) and most of the spinocerebellar ataxias (1–4). Ex-
pansions can arise during inheritance in all these diseases,
and some also display somatic expansions in affected tis-
sue. Expansions determine whether disease will ensue, at
what age and the speed of disease progression. Thus there
is substantial interest in understanding the mechanisms of
CTG•CAG repeat expansion to generate new insights into
these diseases and to identify possible therapeutic avenues
(2–4).
The high frequency of CTG•CAG repeat expansions in
both disease and in model systems suggests an active muta-
genic process that is driven by the presence, not the absence,
of specific proteins. Candidate gene approaches, first in mice
and subsequently in other systems, identified the DNA mis-
match repair protein MutS as a key driver of expansions.
MutS is a heterodimeric complex of Msh2 and Msh3 sub-
units (5,6). Mouse knockouts of either Msh2 or Msh3 block
nearly all inherited and somatic expansions in HD and
DM1 animals (7–12). In contrast, there are modest to no de-
tectable effects on expansions in knockouts of Msh6, which
encodes the MutS-specific Msh6 subunit (9,12–14). The
largest Msh6−/− effect was restricted to maternal transmis-
sion in DM1 mice where the frequency of expansions was
reduced somewhat (13). The dependence of expansions on
Msh2 and Msh3 also extends to a mouse model of Fragile X
associated disorders, where expansions of the CGG•CCG
repeat are driven primarily by MutS (15–17). Studies in
human cells and yeast indicate a similar requirement for
MutS. In human cells, RNA interference against Msh3
or Msh2 but not Msh6 substantially reduced expansion fre-
quencies (18–20). Yeast msh3 mutants but not msh6 mutants
showed a substantial reduction in expansion frequency (21)
and yeast Msh3 has been shown to drive dynamic (ongo-
ing) expansions (22). It is noteworthy that, collectively, these
studies utilized starting CTG•CAG tracts ranging from 22
to 800 repeats. Thus MutS is the relevant eukaryotic MutS
complex for CTG•CAG repeat expansions, and it can drive
expansions that originate from a very wide range of repeat
sizes.
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The key role of MutS in driving expansions engenders
significant interest in how the biochemical features of this
protein complex cause expansions. The abundance of Msh3
is one relevant feature, judging by Msh3+/− mice (13) or
RNAi knockdowns of Msh3 in human cells (18,20) where
reduced Msh3 levels correlated with lower expansion fre-
quencies. It has been assumed in these studies, but not di-
rectly tested, that reduced levels of Msh3 decrease the abun-
dance of MutS. Furthermore, to our knowledge there have
been no reports of the effect of Msh3 overexpression on
triplet repeat expansions. Overexpression of human Msh3
has been directly shown to lead to high levels of MutS,
with significant outcomes on DNA mismatch repair effi-
ciency and genetic mutability (23).
A second important feature of MutS is its ATPase ac-
tivity. Both Msh2 and Msh3 subunits bind and hydrolyze
ATP (12,24–26). The ATPase activity of MutS is impor-
tant in a misrepair model, which envisions a mismatch re-
pair reaction at triplet repeats where DNA resynthesis goes
awry to add too many repeats (27). The misrepair model
predicts a requirement for ATP hydrolysis by the Msh3 sub-
unit (26). In an attempt to address this prediction, a study
by Tome and colleagues (28) examined expansions in DM1
mice with an Msh2 G674A mutation, which impairs its AT-
Pase function. These mice showed large reductions in both
inherited and somatic CTG repeat expansions. However,
the Msh2-G674A protein was expressed at reduced levels,
which might explain the loss of expansions as due to lower
levels of MutS. Furthermore, the purified human MutS
containing Msh2G674A was subsequently reported to bind
ATP poorly (26), providing another possible reason for low
expansion levels unrelated to ATP hydrolysis per se. Thus it
remains unclear if ATP hydrolysis by Msh3 is required for
driving expansions.
Polymorphisms in the Msh3 gene have also been reported
as being important effectors of CTG•CAG repeat expan-
sions. Different mouse backgrounds harboring an identical
expanded HD transgene showed dramatically different pro-
clivities towards somatic expansions (29). This phenotype
was mapped to Msh3, and seven polymorphisms were de-
scribed. The major effect of these polymorphisms appeared
to be on Msh3 protein stability (29) although biochemi-
cal deficiencies could not be ruled out. Similarly, a human
Msh3 polymorphism identified in regression studies was as-
sociated with levels of somatic instability in the blood of
DM1 patients (30). This human polymorphism, T1045A,
alters an amino acid close to the ATPase site of Msh3. Thus
it is possible, but untested, that T1045A may alter the AT-
Pase activity of human Msh3 and therefore affect repeat ex-
pansions (30).
The work summarized above provides information about
how MutS abundance, Msh3 ATPase function and Msh3
polymorphisms affect CTG•CAG repeat expansions. How-
ever, the disparate experimental systems and the complica-
tion of altered Msh3 abundance in some variants have pre-
cluded more definite conclusions. The aim of the current
study was to gain additional insights into the mechanism
of how MutS promotes CTG•CAG repeat expansions in
human cells. We describe the development of a novel experi-
mental platform to more thoroughly investigate the roles of
MutS abundance, Msh3 ATPase function and Msh3 poly-
morphisms.
MATERIALS AND METHODS
Shuttle vector assays and analysis of expansion or contraction
frequencies
The SVG-A shuttle vector assay was previously described
(18,31–33). This selective genetic assay allows examination
of expansions or contractions of trinucleotide repeats that
occur in human SVG-A cells during cell culture (Supple-
mentary Figure S1). SVG-A cells are immortalized astro-
cytes (34,35) that support expansions in culture (18,33,36).
For analysis of expansions, a shuttle vector with a CAN1
reporter was used (Supplementary Figure S1B). Similarly,
contractions were assayed using the shuttle vector with
URA3 as the reporter gene (Supplementary Figure S1C).
Briefly, on day 0 cells were seeded at 4.0 × 105 cells per
60 mm2 tissue culture dish (Sarstedt) in complete media
(DMEM, 10% FBS, pen/strep, SIGMA). Forty-eight hours
after seeding, cells were transfected with 7 g of the shut-
tle vector in a liposome-mediated transfection using Lipo-
fectamine 2000® as transfection agent (Invitrogen-Thermo
Fisher Scientific). On day 4, cells were harvested and sam-
ples were taken for expansion/contraction assay and for
Immunoblot analysis. For expansion/contraction analysis,
the plasmid DNA was extracted by Hirt’s alkaline lysis (37)
and concentrated using Amicon Ultra 50K centrifugal filter
units (Millipore). Following ethanol precipitation, purified
plasmid DNA was digested by DpnI (New England Biolabs)
to remove any unreplicated plasmid. DNA was then trans-
formed into Saccharomyces cerevisiae for measurement of
canavanine resistance (100 g/ml) to assess expansions or
measurement of Ura+ phenotype to measure contractions.
In both cases, the number of total transformants was mea-
sured by restoration of a His+ phenotype to the cells due
to the presence of HIS3 gene as a selectable marker on
the shuttle vector. Expansions and contractions were con-
firmed by PCR as described previously (31–33). Expansion
frequencies were calculated as (number His+ CanR colonies
/number His+ colonies) × (fraction of events confirmed by
PCR). Contraction frequencies were calculated similarly ex-
cept using Ura+ instead of CanR.
Creation of Msh3−/− cell line
A homozygous Msh3−/− SVG-A cell line was created
using CRISPR/Cas9. Guide RNA primers were de-
signed to target exon 2 of Msh3 gene using the CRISPR
design program available at crispr.mit.edu and syn-
thesised by Eurofins Genomics (M3g5F-5′ TTTCTT
GGCTTTATATATCTTGTGGAAAGGACGAAACA
CCGCAGGCCCATCATTTTCCAA-3′), (M3g5R-5′
GACTAGCCTTATTTTAACTTGCTATTTCTAGCTC
TAAAACTTGGAAAATGATGGGCCTGC-3′). SVG-A
cells were seeded at a density of 4.0 × 105 in a 60 mm2 dish
(Sarstedt) and transfected with a combination of the gRNA
plasmid (Addgene), CRISPR hCas9 WT plasmid (Ad-
dgene) and a pMSCV puro resistance plasmid (Clontech
Laboratories) using Lipofectamine 2000®. Forty-eight
hours after transfection, the cells were re-suspended in
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puromycin-supplemented media (700 ng/ml) and trans-
ferred to a 10 cm2 tissue culture dish, ∼200 cells per dish.
Selection for puromycin resistance was applied for 14
days and formation of single cell colonies was observed.
Subsequently, selection pressure was removed and colonies
were grown in complete media and subsequently screened
for Msh3 protein expression by immunoblotting for Msh3
as described below. Disruption to the Msh3 gene sequence
was confirmed by TA PCR and Sanger sequencing (Source
Bioscience).
Creation of Msh3 derivative cell lines
To create Msh3 variant cell lines, an Msh3 expression plas-
mid was created using Image clone cDNA (Source Bio-
science, MGC: 164408, IMAGE: 40146467) ligated into a
pcDNA 3.1 neo expression plasmid vector (Thermo Fisher
Scientific). ATPase mutants and polymorphic variants of
Msh3 were created by site-directed mutagenesis (Q5® site
directed mutagenesis kit, New England Biolabs). Primers
were designed using the NEBasechanger application (New
England Biolabs) and are listed in Supplementary Table S1.
SVG Msh3 −/- cells were seeded at a density of 4.0 × 105 in
a 60 mm2 dish and co-transfected with the WT or variant
Msh3 expression plasmid and a pMSCVhygro resistance
plasmid (Clontech Laboratories). Forty-eight hours follow-
ing transfection, cells were resuspended in hygromycin sup-
plemented media (400 ng/ml) and diluted to 200 cells/10
cm2 dish to allow formation of colonies. Protein expression
was measured in individual clones by immunoblot analysis.
Immunoblot analysis
To assess protein expression of Msh2, Msh3 and Msh6,
SVG-A cells were harvested by washing in ice-cold 1× PBS
(137 mM NaCl, 2.7 mM KCl, 10 mM phosphate pH 7.4)
and re-suspended in 1× RIPA buffer (0.1% SDS, 0.1% Tri-
ton X-100, 0.1% sodium deoxylcholate, 5 mM EDTA, 100
mM PMSF and mammalian protease inhibitors (Fisher Sci-
entific #12841640) at 1× concentration). Following incuba-
tion on ice for 30 min, cell pellets were disrupted in a water-
bath sonicator for 4 cycles of 15 s and then centrifuged at
16 200 × g @ 4◦C. Supernatants containing protein sam-
ples were retained. Protein concentrations were measured
using DC-assay (Bio-Rad Laboratories). Samples contain-
ing 50–100 g of total protein were mixed with 4× laemmli
buffer (containing 20 mM DTT) at 95◦C for 5 min. Fol-
lowing SDS-PAGE on 10% gels, proteins were transferred
to a nitrocellulose membrane and blocked for 1 h at room
temperature in 5% milk/PBS + 0.1% Tween. Following
blocking, membranes were incubated overnight at 4◦C with
Msh3 primary antibody (BD Biosciences, 611390, mouse,
1/1000 dilution, targets an epitope between amino acids
136–349; or Abcam 154251, rabbit, 1/1,000 dilution, tar-
gets an epitope between residues 916–1137), Msh2 primary
antibody (Calbiochem, NA26, mouse, 1/1000 dilution) or
Msh6 primary antibody (BD Biosciences, 610919, Mouse,
1/1000 dilution). Incubation with Actin primary antibody
(Sigma, A2066, Rabbit, 1/1000) and subsequent detection
was performed simultaneously as a loading control. Fol-
lowing overnight incubation with primary antibodies, mem-
branes were washed and incubated with infrared-labelled
secondary antibodies from Li-Cor Biosciences, IRDye®
800CW goat anti-mouse IgG (P/N 925-32210) or IRDye®
800CW goat anti-rabbit IgG (P/N 925-3211). Immunoreac-
tive bands were visualised and quantified using Odyssey In-
frared Imaging systems and software (Li-Cor Biosciences).
Co-immunoprecipitation
SVG-A cells or derivatives were grown to near-confluence in
tissue culture flasks of 175 cm2 surface area. All subsequent
steps were performed at 0–4◦ unless otherwise noted. Cell
culture media was removed and the cells were washed with
PBS. Cells were scraped off into fresh PBS and collected by
centrifugation at 425 × g for 5 min. Cell pellets were washed
once in fresh PBS, centrifuged again and the cell pellet was
drained. Whole cell lysates were prepared by adding 0.5 ml
IP buffer (25 mM HEPES–KOH pH 7.5, 125 mM NaCl, 5
mM MgCl2, 0.1 mM EDTA, 0.05% Triton X-100 and mam-
malian protease inhibitors (Fisher Scientific #12841640) at
1× concentration). Following 30 min incubation on ice with
occasional gentle pipetting, lysates were clarified by cen-
trifugation at 15 000 × g for 20 min. Protein concentrations
were determined by DC assay (Bio-Rad Laboratories). Cell
lysate containing 2 mg protein was added to protein A-
sepharose beads (originally 30 l slurry; New England Bi-
olabs #S1425S) in IP buffer to which 3 g of anti-Msh3
antibody ab69619 (Abcam) had previously been bound. Af-
ter overnight mixing of the 0.5 ml mixture, the beads were
removed magnetically, and then washed three times in IP
buffer. Bound proteins were eluted in 1× Laemmli SDS
sample buffer at 95◦C for 5 min. Protein mixtures were sep-
arated on 8% SDS-PAGE followed by immunoblotting for
Msh3, Msh2 and actin as described earlier. Msh3 and Msh2
protein abundance in the immunoprecipitated samples was
normalized to the value for Msh3 and Msh2 abundance
from the Msh3+/+ samples.
Expression and purification of MutS
Human MSH3 gene encoding a glutamate to alanine
substitution at amino acid residue 976 (Msh3E976A) was
cloned into pFastBac-HT b using the Gibson assembly kit
(New England BioLab). Wild type MutS (Msh2-Msh3)
or MutS-EA (Msh2-Msh3E976A) were expressed in in-
sect cells co-infected with baculoviruses carrying Msh2 and
Msh3 or Msh2 and Msh3E976A, respectively. Both wild type
and mutant MutS proteins were purified to near homo-
geneity as previously described (38). Protein concentrations
were determined by Bio-Rad Protein Assay kit (Bio-Rad
Laboratories, Hercules, CA, USA).
ATPase assays
ATPase activity of MutS proteins was assayed in 20
L reactions containing 25 mM HEPES•KOH (pH 7.6),
4 mM MgCl2, 0.1 Ci [ -32P]ATP, and 50 nM MutS
or MutSE976A in the presence or absence of 5 nM 50-
mer oligonucleotide duplex containing a two-nucleotide
insertion/deletion heterology. After incubation at 37◦C for
20 min, the individual reactions were terminated and frac-
tionated through a 20% denaturing polyacrylamide gel. 32P-
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containing species were detected by autoradiography and
quantified using ImageJ.
Statistical analysis
All P-values for repeat instability and immunoprecipitation
experiments were determined by one-tailed Student’s t-test.
Unpaired t-test was used to measure P values for ATPase
assays. P- and n-values for each data set are specified in Sup-
plementary Table S2 and, where statistical significance was
reached, in the relevant figure legend.
RESULTS
Msh3−/− cells are selectively deficient for MutS and defec-
tive for CTG•CAG repeat expansions but not contractions
We sought to create a human cell knockout of Msh3 to selec-
tively eliminate MutS. SVG-A astrocytic cells were chosen
because they are one of the few tissue culture models that
supports TNR expansions in culture (18,33,36). Further-
more, siRNA knockdown of Msh2 or Msh3 reduce expan-
sion frequencies in these cells, indicating that MutS is im-
portant for expansions (18). In vivo, astrocytes, like neurons,
show expansions in HD patients (39). Exon 2 of the Msh3
gene was targeted by CRISPR/Cas9 (Figure 1A). Potential
knockouts were screened by immunoblot for loss of Msh3
protein expression. A candidate clone was further analysed
by DNA sequencing. This clone showed a nine-base pair
deletion in Msh3 that eliminates the codons for amino acids
116–118. More extensive immunoblotting with an antibody
raised against amino acids 136–349 of Msh3 revealed loss
of protein expression (Figure 1B and C), consistent with
creation of an Msh3−/− cell line. Quantification indicated
a residual level of Msh3 protein at 2% wild type levels (Fig-
ure 1C). The loss of Msh3 expression was confirmed by im-
munoblot using a second anti-Msh3 antibody raised against
amino acids 916–1137 (Supplementary Figure S2). Expres-
sion of Msh2 and Msh6 proteins appeared somewhat ele-
vated in Msh3−/− cells, although the change was not statis-
tically significant compared to wild type cells (Figure 1C).
Similar to previous reports in cancer cell lines (40,41), cell
growth is not detectably affected by loss of Msh3 (Figure
1D). This Msh3−/− cell line was chosen for further charac-
terization.
(CTG•CAG)22 expansion frequency of the Msh3−/− cells
was measured in parallel to the starting wild type Msh3+/+
cells (Supplementary Figure S1B). Msh3−/− cells were de-
fective for expansions, losing approximately three-quarters
of activity (Figure 1E). This loss in expansion activity is
consistent with results from mouse knockouts of Msh3, hu-
man cell knockdowns and yeast mutants (9,12,13,18–21).
The size range of expansions, from +4 to +10 repeats, was
similar in both the Msh3−/− cells and the wild type cell con-
trol, consistent with the idea that loss of Msh3 blocks ex-
pansions approximately equally across this size range. Ex-
pansions were not completely eliminated in the Msh3−/-cell
line (Figure 1E). As discussed later, other proteins may be
responsible for a minor fraction of triplet repeat expansions
in human cells.
The role of MutS in TNR contractions is less clear.
Some mouse knockouts of Msh3 show a CTG•CAG re-
peat contraction bias in Msh3−/− animals (13) whereas
other lines do not (9,12,14). Biochemical studies in human
cell extracts led to the conclusion that CTG•CAG repeat
contractions were enhanced in the absence of MutS (42).
We therefore examined the Msh3−/- SVG-A cells for con-
tractions (Supplementary Figure S1C). The results showed
no significant change in contraction frequency between
Msh3−/− cells and wild type (Figure 1F).
In summary, this approach led to a human Msh3−/−
cell line that is selectively deficient in MutS, while the
Msh2 and Msh6 components of MutS are left intact. The
Msh3−/− cells are defective in CTG•CAG repeat expan-
sions but not contractions.
Overexpression of Msh3 causes an increase in expansion fre-
quency and drives increased MutS formation
The Msh3−/− cells provide a cellular platform for adding
back Msh3 expressed from plasmids and selection of stable
integrants. This allows expression of wild type or variant
Msh3 at controllable levels as a way to measure the bio-
chemical activity of MutS on expansion activity. In this
way, direct comparisons can be made between situations
where MutS is altered.
Msh3 abundance in mice is limiting for expansion activ-
ity, based on partial loss of expansions in Msh3+/− animals
where Msh3 abundance is reduced (13). To see if Msh3 over-
expression drives elevated levels of expansions, Msh3−/−
cells were transfected with a cDNA clone encoding wild
type Msh3. Stable integrants that express higher than nor-
mal levels of the protein were identified by immunoblot. The
Msh31.7X cell line restored Msh3 expression to 1.7 times wild
type expression (Figure 2A and B). Msh2 and Msh6 pro-
tein expression were somewhat elevated compared to wild
type but only the Msh6 abundance was statistically sig-
nificantly altered (Figure 2B). It is unclear why the abun-
dance of Msh2 and Msh6 was elevated in these cells. There
was no detectable difference in cell growth rate upon over-
expression of Msh3 (Supplementary Figure S3). When as-
sayed for expansions, the overexpressing cells showed a sig-
nificant increase in expansions compared to the Msh3−/−
background (Figure 2C). This indicates rescue of the expan-
sion phenotype in the Msh31.7X cells. Msh3 overexpression
also led to an increased expansion frequency compared to
wild type cells, although this difference was not statistically
significant. The results are consistent with a direct relation-
ship between Msh3 abundance and CTG•CAG expansion
frequency (Figure 2C). The range of expansion sizes was
similar between wild type and overexpressing cells (+4 to
+10 repeats, Msh3+/+; +4 to +12 repeats Msh31.7X), as was
the weighted average expansion size (+6.8 repeats, Msh3+/+;
+7.2 repeats Msh31.7X). In contrast to the effects on expan-
sion frequencies, there was no significant difference detected
in contraction frequency in Msh31.7X cells compared to wild
type controls (Figure 2D).
To evaluate whether the abundance of MutS complex
parallels Msh3 levels, co-immunoprecipitation (co-IP) was
performed using antibodies against Msh3, followed by im-
munoblot analysis of Msh3 and Msh2 (Figure 2E). Control
experiments showed that this protocol was efficient, captur-
ing 84 ± 11% of all Msh3 (Supplementary Figure 4). To test
Downloaded from https://academic.oup.com/nar/article-abstract/45/17/10068/3984559
by University of Kentucky Libraries user
on 18 July 2018
10072 Nucleic Acids Research, 2017, Vol. 45, No. 17
Figure 1. Loss of Msh3 causes a defect in CTG repeat expansions but not contractions. (A) Schematic showing predicted CRISPR/Cas9 cut site in exon 2 of
human Msh3 gene. Sequencing results show in-frame nine base pair deletion with corresponding loss of codons for amino acids 116–118. (B) Representative
immunoblot with an antibody against Msh3 residues 136–349, showing loss of Msh3 expression in Msh3−/-cells in comparison to Msh3+/+ wild type cell
line. Expression of Msh2 and Msh6 was retained. (C) Quantitative analysis of Msh protein expression in Msh3+/+ and Msh3−/-cell line, normalised to
actin and relative to Msh3+/+. n = 9 for Msh3 levels; n = 7 for Msh3+/+Msh2 and Msh6 protein levels; and n = 6 for Msh3−/-Msh2 and Msh6 protein
levels. *P = 2.23 × 10−20. (D) Growth curve analysis of Msh3+/+and Msh3−/-cell lines, n = 3. (E) Expansion frequencies of Msh3+/+and Msh3−/− cell
lines, n = 3 for Msh3+/+and n = 4 for Msh3−/−, *P = 0.0019. (F) Contraction frequencies of Msh3+/+and Msh3−/− cell lines, n = 3. For panels C-F, error
bars denote ±SEM.
MutS abundance, an Msh32.9X cell line expressing Msh3 at
2.9× wild type levels was utilized for greater sensitivity. The
input samples show the expected gradation of Msh3 abun-
dance, whereas Msh2 levels were approximately equal (Fig-
ure 2E). In the co-IP samples, however, the levels of Msh3
and Msh2 both increase, consistent with a higher abun-
dance of MutS complex (Figure 2E). Quantitative analysis
(n = 4) showed that increased expression of Msh3 at 2.9×
wild type levels resulted in more MutS complex formation
at 2.8× normal levels (Figure 2F). We conclude that add-
back cells overexpressing Msh3 form higher levels of MutS
complex and exhibit enhanced frequency of CTG•CAG re-
peat expansions. Like the Msh31.7X cell line, the contraction
frequency with the Msh32.9Xcells (0.021; P = 0.29, n = 3)
was not significantly different from Msh3+/+ control cells
(0.026).
Data from the co-IP in Msh3+/+ cells allowed an esti-
mation of the normal abundance of MutS compared to
MutS. By quantifying the Msh3 and Msh2 levels in the
input and flow-through fractions of the co-IP protocol, the
proportion of Msh2 protein present in MutS can be esti-
mated (Supplementary Figure S4A). One example of pri-
mary data gave a value of 27% of all Msh2 protein captured
as MutS (Supplementary Figure S4B). Overall results (n
= 4) showed that 26 ± 6% of total Msh2 was complexed in
MutS in SVG-A cells, giving an estimation of the ratio of
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Figure 2. Msh3 overexpression cell line shows increased expansion frequency and increased MutS formation with no effect on contraction frequency. (A)
Representative immunoblot showing Msh3 protein expression in Msh3 add-back cell line (Msh31.7X) in comparison to Msh3+/+and Msh3−/− cell lines.
(B) Quantitative analysis of Msh3 protein expression normalised to actin and relative to Msh3+/+cell line. Msh3 add-back cell line has an average Msh3
expression level of 1.7 times wild type expression. n = 9 for Msh3 protein expression in all cell lines, n = 7 for Msh2 and Msh6 protein levels in Msh3+/+
cell lines, n = 6 for Msh2 and Msh6 protein levels in Msh3−/− cell line and n = 5 for Msh2 and Msh6 protein levels in Msh31.7xcell line. *P = 2.23 ×
10−20 and **P = 1.87 × 10−6, both compared to Msh3 level in Msh3+/+cells. ***P = 0.032 compared to Msh6 level in Msh3+/+cells. (C) Expansion
frequencies for Msh3−/−, Msh3+/+ and Msh31.7Xcell lines. n = 4 for Msh3−/-and n = 3 for Msh3+/+and Msh31.7X. *P = 0.029 compared to wild type. (D)
Contraction frequencies of Msh3−/−, Msh3+/+and Msh31.7Xcell lines, n = 3. (E) Representative immunoblot for co-immunoprecipitation of Msh3 and
Msh2 and investigation of MutS formation in Msh3−/−, Msh3+/+ and Msh32.9X cell lines. (F) Quantitative analysis of immunoprecipitated Msh3 and
Msh2 protein abundance, n = 4 for all samples. *P = 5.44 × 10−13 for Msh3 and P = 4.30 × 10−11 for Msh2 compared to wild type; and **P = 1.66 ×
10−4 for Msh3 and P = 4.96 × 10−3 for Msh2 compared to wild type. For panels B, C, D and F error bars denote ±SEM.
26% MutS to 74% MutS (Supplementary Figure S4C).
These values are in reasonable agreement with the report by
Drummond et al. (23) that ∼15% of total Msh2 in HL-60
cells is complexed with Msh3 as MutS, with the remaining
85% complexed with Msh6 to form MutS.
Msh3 ATP hydrolysis activity is required for CTG•CAG re-
peat expansions
Both Msh2 and Msh3 subunits of MutS bind and hy-
drolyse ATP (12,24–26). To investigate the requirement for
Msh3 ATPase function in expansions, the codon for glu-
tamate 976 was mutated to alanine (E976A) in the cDNA
plasmid encoding Msh3 (Figure 3A). This creates an Msh3
Walker B mutant that is predicted to bind ATP but be de-
fective for hydrolysis. This prediction is based in part on
biochemical analysis of purified yeast MutS protein bear-
ing the equivalent E768A alteration in Msh2; this protein
was shown to be proficient for binding ATP but defective in
its hydrolysis (43–45). The human Msh3E976A plasmid was
transfected into Msh3−/− cells and stable integrants were
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Figure 3. Msh3E976A ATPase Walker B mutant shows a decreased expansion frequency compared to Msh3+/+ wild type. (A) Schematic showing Walker
B motif consensus sequence and the E976A mutation, ‘h’ denotes any hydrophobic amino acid. (B) Representative immunoblot showing Msh protein
expression in Msh3+/+ and Msh3E976Acell lines. Msh3E976A cells show Msh3 expression at near wild type levels. (C) Representative immunoblot of co-
immunoprecipitation of Msh3 and Msh2 and MutS formation in Msh3+/+and Msh3E976A cell lines. (D) Expansion frequencies for Msh3E976A cell line in
comparison to Msh3+/+, n = 3, *P = 0.037. (E) Contraction frequencies of Msh3E976Aand Msh3+/+ cell lines, n = 5 for Msh3+/+and n = 4 for Msh3E976A.
(F) Representative ATPase analysis of MutS and MutS-Msh3E976A (MutS EA) in the absence or presence of mismatched DNA containing a two-
nucleotide insertion/deletion mispair. Pi, [32P]phosphate. (G) Average ATP hydrolysis activity, n = 3. *P = 0.028 compared to wild type MutS assayed
without DNA (unshaded bars); **P = 0.001 compared to wild type MutS assayed with DNA (shaded bars). For panels D, E and G, error bars denote
±SEM.
screened by immunoblot to identify clones that expressed
Msh3 at near wild-type levels. A clone was chosen with
Msh3E976A protein levels indistinguishable (101%; n = 4)
from wild type (Figure 3B). This clone allows measurement
of the requirement for Msh3 ATPase function in expansions
at normal levels of the protein. There was no significant cell
growth difference observed when compared with Msh3+/+
cell line (Supplementary Figure S5A). Analysis of MutS
complex formation in Msh3E976A cells, measured by co-IP
and subsequent immunoblot analysis, reveals that there is
MutS complex formation in the Msh3E976A cell line (Fig-
ure 3C) but at ∼50–70% the level compared to Msh3+/+
(Supplementary Figure S5B). Thus, the E976A variant ap-
pears partially defective in forming or maintaining a stable
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MutS complex. In contrast to the partial defect in MutS
stability, the Msh3E976A cell line showed a strong deficiency
in expansions (Figure 3D). The extent of this expansion de-
fect by Msh3E976A cells was comparable in magnitude to that
seen in the Msh3−/− line (Figure 1E). This finding suggests
that ATP hydrolysis by Msh3 is required for CTG•CAG re-
peat expansions in this system. In contrast to expansions,
there was no statistically significant difference (P = 0.06) in
contraction frequencies between Msh3E976A cells and wild
type controls (Figure 3E). To test whether Msh3E976A pro-
tein is defective in ATPase function, both wild type MutS
and the mutant complex containing Msh3E976A were puri-
fied and assayed for ATPase function. Representative assay
results showed that wild type MutS was active as an AT-
Pase and that this activity could be moderately stimulated
in the presence of a two-nucleotide insertion/deletion mi-
spair (Figure 3F). In contrast, MutS-Msh3E976A showed
only partial ATPase activity with little stimulation by mis-
matched DNA. Cumulative results from three independent
assays confirmed that MutS-Msh3E976A ATPase activity is
significantly reduced compared to wild type protein under
these assay conditions (Figure 3G).
Normal levels of expansions in two naturally-occurring poly-
morphic variants of Msh3
Studies of TNR expansions in different strains of mice
showed variable expansion frequencies due to natural
polymorphisms in Msh3 (29). One polymorphism, mouse
Msh3T321I, falls in a highly conserved region and the
isoleucine variant was proposed to destabilize the protein,
thus causing lower expansion frequencies due to reduced
abundance of Msh3 (29). To distinguish protein abundance
from potential biochemical alterations due to this polymor-
phism, we created the equivalent change to human Msh3,
T363I (Figure 4A). Similarly we tested another Msh3 vari-
ant, T1045A, where the threonine variant is associated with
higher levels of somatic instability in DM1 patients (30).
Our clone of human Msh3 encodes threonine at position
1045, therefore we created the T1045A variant (Figure 4A)
and looked for a decrease in expansions.
Cell lines were identified that express either Msh3T363I
or Msh3T1045A in the Msh3−/− cell background at levels
as close as possible to wild type levels of protein (Figure
4B). Msh3 abundance was estimated by immunoblot at 75%
(T363I) and 71% (T1045A) compared to wild type (Supple-
mentary Figure S6A). MutS complex formation was ob-
served in both cell lines (Figure 4C). Quantification showed
that MutS abundance was reduced in Msh3T363I cells
to ∼60–90% of wild type control (Supplementary Figure
S6B), in line with the expression levels of the variant Msh3
proteins. There was no apparent difference in cell growth
of the Msh3T363I or Msh3T1045A cell lines in comparison to
the Msh3+/+cell line (Supplementary Figure S6C). When
assayed for expansions, there was no statistically signifi-
cant difference observed in expansion frequency between
the polymorphic cell lines and Msh3+/+cell line (Figure 4D).
We note that the prediction for the Msh3T1045A cells was for
fewer expansions. These results are consistent with a previ-
ous conclusion (29) that the major effect of the mouse T321I
polymorphism (T363I in human) is on Msh3 abundance.
DISCUSSION
This study addressed several previously untested aspects
of MutS that are relevant to its ability to promote
CTG•CAG repeat expansions in human cells. The ap-
proach was to create a novel cell platform that is selectively
deficient in MutS by using CRISPR/Cas9 to knock out
Msh3. The resulting Msh3−/− cells were largely defective
in driving expansions. This Msh3−/− cell line allowed add
back of plasmids expressing Msh3 to test key biochemi-
cal features of MutS in a single, isogenic system that di-
rectly measures CTG•CAG repeat expansions as the key
functional outcome. Moreover, the steady state levels of
Msh3 could be controlled to separate the effects of MutS
abundance from potential biochemical changes in the vari-
ant forms of Msh3 that were tested. We show for the first
time that MutS overabundance due to overexpression of
Msh3 tends to drive expansions to high levels, indicating
that expansions are normally limited in these cells by the
levels of MutS. Our results also show that the expansion-
promoting properties of MutS require the ability of Msh3
to hydrolyze ATP. The add back of two naturally occurring
polymorphic variants of Msh3 gave results consistent with
the idea that the major effect of these variations is on MutS
abundance. The mechanistic implications of these findings
are discussed below.
The Msh3−/− cells are ∼98% deficient in Msh3 based on
DNA sequencing and immunoblotting with two different
anti-Msh3 antibodies. We presume the residual signal is due
to low levels of mutant Msh3, although it is difficult to rule
out the possibility of a non-specific signal. The cells grow
at normal rates and the components of MutS are still ex-
pressed (Figure 1), thus the cells are selectively deficient in
MutS. Expansion assays of the Msh3−/− cells, in parallel
to the wild type Msh3+/+ cell line, showed a ∼75% reduction
in expansion activity upon loss of Msh3 expression. Thus
a large majority of CTG•CAG repeat expansions are de-
pendent on MutS, similar to numerous findings in mouse
knockout studies of Msh3 (9,12–14), siRNA knockdowns
in human cells (18–20) and msh3 mutants in yeast (21).
The residual ∼25% of expansions seen in Msh3−/− cells
might be attributable to other pathways of expansion. For
example, residual germline expansions in Msh3−/− Fragile
X mice were attributed to the activity of MutS (16,17).
Nevertheless there is a striking reduction in expansions in
Msh3−/− cells that are selectively deficient for MutS.
Another key question centers on MutS abundance and
its role in promoting expansions in human cells. A study us-
ing Msh3+/− heterozygous mice showed that reduced Msh3
abundance was associated with a decrease in expansions
(13), suggesting that expansions are limited by the level of
Msh3 protein, and by inference, MutS. A separate ques-
tion is whether the normal abundance of MutS limits ex-
pansions. To address this, we created cell lines that overex-
press Msh3 (Figure 2). There was a clear increase in ex-
pansion activity for the Msh31.7X cells over the Msh3−/−
line, indicating rescue of the expansion defect by add back
of wild type Msh3. Expansions in Msh31.7X cells were also
elevated over wild type, although not to a statistically sig-
nificant degree. Expansion activity in the series Msh3−/−,
wild type and Msh31.7X cells is consistent with a dose-
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Figure 4. Msh3 polymorphic cell lines show no significant differ-
ence in expansion frequency in comparison to Msh3+/+ cell line. (A)
Schematic showing polymorphic changes to Msh3 sequence. (B) Repre-
sentative immunoblot showing Msh protein expression in Msh3T363Iand
Msh3T1045Acell lines at comparable expression levels to Msh3+/+wild type
cells. (C) Representative immunoblot of co-immunoprecipitated Msh3 and
Msh2 showing MutS complex formation in Msh3T363Iand Msh3T1045A
cell lines alongside Msh3+/+cells. (D) Expansion frequencies for polymor-
phic Msh3 cell lines assayed in parallel to Msh3+/+. Error bars denote
±SEM, n = 3.
dependent relationship between Msh3 abundance and ex-
pansion frequency above wild type levels (Figure 2C). An-
other overexpressing cell line, Msh32.9x, showed high levels
of MutS complex formation, thus proving the assump-
tion that higher levels of Msh3 increase the abundance of
MutS. The direct correlation between Msh3 overexpres-
sion and enhanced abundance of MutS is consistent with
a previous report (23). Overall, these findings support the
conclusion that increased Msh3 abundance, leading to in-
creased levels of MutS complex, directly affects the likeli-
hood of CTG•CAG expansions in human cells.
To address another key but untested feature of expansion
mechanism, we investigated the ability of Msh3 to hydrolyze
ATP. This experiment tested the misrepair model of expan-
sions (27), which predicts that Msh3 must both bind and
hydrolyze ATP (26). A previous study in mice investigated
Msh2 ATPase function using the Msh2G674A mutant and
found that animals harboring this mutant were defective for
expansions. However, the mutant Msh2 was expressed at
lower levels than wild type, indicating that the expansion de-
fect might be due to MutS abundance (28). Moreover, bio-
chemical studies using purified MutS containing the mu-
tant Msh2 protein showed a decreased ability to bind ATP
(26). Thus, it has not been possible to distinguish clearly be-
tween protein abundance issues, nor between ATP hydrolyis
versus binding, on expansions. We created a mutation in the
Walker B motif, Msh3E976A, to help address this conundrum
(Figure 3). The glutamate in the Walker B motif is required
for efficient hydrolysis; upon mutation of this glutamate, hy-
drolysis of ATP is ablated but binding is unaffected (46).
Biochemical studies of purified yeast MutS proved that
mutant Msh2 protein carrying the Walker B E768A alter-
ation caused defects in hydrolysis but not binding of ATP
(43–45). Our Msh3E976A cell line expresses Msh3E976A at
100% of wild type levels, thus avoiding the issue of Msh3
protein abundance. Msh3E976A forms MutS complex al-
though at 50–70% wild type level. This suggests a partial
defect in MutS complex formation and/or maintenance
in Msh3E976Acells, perhaps due to increased dissociation of
Msh3E976A from Msh2. In contrast to the partial defect
in MutS formation, the Msh3E976A cells showed a much
more severe loss in expansion activity, down to a level that is
comparable to the Msh3−/− cells. ATPase assays on purified
proteins showed the E976A alteration significantly reduced
hydrolysis activity compared to wild type control protein.
We interpret this to mean that ATP hydrolysis by Msh3 is re-
quired for the majority of CTG•CAG repeat expansions in
human cells, consistent with the misrepair model for TNR
expansions (26,27). The misrepair model is also consistent
with the requirement for the MutL homologs Pms2, Mlh1
and Mlh3 in driving expansions, as evidenced by the re-
duced frequency of somatic expansions in knockout mice
(27,47).
The cell system described here also allowed further in-
vestigation of the recent discovery of naturally occuring
Msh3 polymorphic variants that impact expansion ac-
tivity (Figure 4). We tested two polymorphic variants:
human Msh3T363I to mimic mouse Msh3T321I, which
was suggested to contribute to protein stability (29); and
Msh3T1045A, where the alanine variant is predicted to re-
duce expansion frequencies. Both cell lines, Msh3T363I and
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Msh3T1045A, have slightly lower Msh3 protein expression
and MutS complex formation as wild type Msh3+/+cells.
However, there was no detectable difference in expansion
frequencies compared to wild type controls, suggesting that
the variable expansion frequencies observed in studies of
mouse and human Msh3 polymorphisms were more likely
due to decreased Msh3 abundance rather than a biochemi-
cal defect. It is noted that our human Msh3 expression clone
carries a mixture of polymorphisms, with some amino acids
correlating with high expansion frequencies in mouse and
other positions that correlate with low frequencies of expan-
sion. Thus it is possible that changing just one polymorphic
site, T363I, may not be sufficient to reveal a strong expan-
sion phenotype. Regarding the human variant, T1045A, in-
spection of the MutS crystal structure shows that position
1045 is in an unstructured stretch of 17 amino acids that
is poorly conserved between MutS homologs (25). We infer
that T1045A likely does not affect ATP hydrolysis based on
the observation that Msh3T1045A cells retain normal levels
of expansions, in contrast to the loss of expansions in cells
containing the Walker B motif mutation Msh3E976A.
In contrast to effects on CTG•CAG repeat expansions,
assays of contractions showed no significant difference in
contraction frequencies between Msh3−/− cells, wild type
cells, Msh3 overexpressing cells or Msh3E976A cells. This re-
sult concurs with most (9,12,14) but not all (13) previous
reports of Msh3 knockout mice where no major changes to
inherited or somatic contractions were found. We also note
that contractions in human cells are also independent of
Mlh1 expression (31). In our hands, loss of either the MutS
homolog Msh3 or the MutL homolog Mlh1 did not affect
contractions. We acknowledge the limited range of contrac-
tions that can be scored by this assay, from -6 to -33 repeats
(Supplementary Figure S1C). Contractions smaller than –6
repeats or greater than –33 repeats would not be revealed. It
is also noted that our shuttle vector assay is driven by SV40
large T antigen, not the normal CDC45-MCM-GINS he-
licase, raising the possibility that mismatch repair proteins
may not interact identically with the replication complex on
the shuttle vector. Alternatively, it is conceivable that the
shuttle vector assay primarily reports events during the first
replication cycle of the SV40-based plasmid, when its im-
mature chromatin structure (48) could mask the activity of
MutS on contractions.
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